Hummingbird Bioscience
5 known investors
Hummingbird Bioscience develops antibody-based therapeutics, including antibody-drug conjugates (ADCs), using proprietary linker-payload and biologics discovery platforms. Its pipeline targets oncology and autoimmune diseases, aiming at precision medicine for patients who do not respond to current treatments.